Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb;67(2):e28089.
doi: 10.1002/pbc.28089. Epub 2019 Nov 14.

Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors

Marta Perez-Somarriba  1 , Maria Luisa Moreno-Tejero  2 , Maria Isabel Rozas  3 , Irene Pelaez  4 , Luis Madero  1 , Alvaro Lassaletta  1
Affiliations
Case Reports

Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors

Marta Perez-Somarriba et al. Pediatr Blood Cancer. 2020 Feb.

Abstract

Intracranial germ cell tumors (GCT) account for less than 5% of all central nervous system tumors in children in Western countries. Approximately 40% are nongerminomatous GCT (NGGCT). Despite correct treatment, 16% to 47% of the patients will relapse. There are no standard approaches in case of recurrence, and treatment in this situation remains a challenge. We report three patients diagnosed with relapsed intracranial NGGCT treated with gemcitabine, paclitaxel, and oxaliplatin, in whom the tumor showed a remarkable response with normalization of tumor markers.

Keywords: GEMPOX; NGGCT; gemcitabine; oxaliplatin; paclitaxel; relapsed intracranial nongerminomatous germ cell tumors.

PubMed Disclaimer

References

REFERENCES

    1. Bowzyk Al-Naeeb A, Murray M, Horan G, et al. Current management of intracranial germ cell tumours. Clin Oncol (R Coll Radiol). 2018;30:204-214.
    1. Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group Study. J Clin Oncol. 2015;33:2464-2471.
    1. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. Int J Cancer. 2017;141:621-635.
    1. Fetcko K, Dey M. Primary central nervous system germ cell tumors: a review and update. Med Res Arch. 2018;6. https://doi.org/10.18103/mra.v6i3.1719.
    1. Smith AA, Weng E, Handler M, et al. Intracranial germ cell tumors: a single institution experience and review of the literature. J Neurooncol. 2004;68:153-159.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources